

Stefan Costinean

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11804947/publications.pdf>

Version: 2024-02-01

35
papers

7,898
citations

172457

29
h-index

361022

35
g-index

36
all docs

36
docs citations

36
times ranked

12309
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15805-15810.	7.1	1,538
2	Modulation of miR-155 and miR-125b Levels following Lipopolysaccharide/TNF- α Stimulation and Their Possible Roles in Regulating the Response to Endotoxin Shock. Journal of Immunology, 2007, 179, 5082-5089.	0.8	1,229
3	Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E μ 4-miR155 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7024-7029.	7.1	1,023
4	Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. Journal of Clinical Investigation, 2012, 122, 2871-2883.	8.2	666
5	Reprogramming of miRNA networks in cancer and leukemia. Genome Research, 2010, 20, 589-599.	5.5	331
6	Modulation of mismatch repair and genomic stability by miR-155. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6982-6987.	7.1	306
7	Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein β are targeted by miR-155 in B cells of E μ 4-MiR-155 transgenic mice. Blood, 2009, 114, 1374-1382.	1.4	278
8	Mutator activity induced by microRNA-155 (<i>miR-155</i>) links inflammation and cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4908-4913.	7.1	226
9	Targeted deletion of <i>Wwox</i> reveals a tumor suppressor function. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3949-3954.	7.1	210
10	Protective role of miR-155 in breast cancer through <i>RAD51</i> targeting impairs homologous recombination after irradiation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4536-4541.	7.1	181
11	Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood, 2009, 114, 3872-3879.	1.4	179
12	miR-155 regulates IFN- β production in natural killer cells. Blood, 2012, 119, 3478-3485.	1.4	177
13	Chronic lymphocytic leukemia modeled in mouse by targeted <i>miR-29</i> expression. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12210-12215.	7.1	167
14	MicroRNA 29 Targets Nuclear Factor- κ B Repressing Factor and Claudin 1 to Increase Intestinal Permeability. Gastroenterology, 2015, 148, 158-169.e8.	1.3	162
15	miR-29ab1 Deficiency Identifies a Negative Feedback Loop Controlling Th1 Bias That Is Dysregulated in Multiple Sclerosis. Journal of Immunology, 2012, 189, 1567-1576.	0.8	161
16	Regulation of acute graft-versus-host disease by microRNA-155. Blood, 2012, 119, 4786-4797.	1.4	128
17	miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the E μ -miR-155 transgenic mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 20047-20052.	7.1	121
18	MicroRNAs, the immune system and rheumatic disease. Nature Clinical Practice Rheumatology, 2008, 4, 534-541.	3.2	117

#	ARTICLE	IF	CITATIONS
19	miR-15b/16-2 deletion promotes B-cell malignancies. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11636-11641.	7.1	98
20	Effect of Rapamycin on Mouse Chronic Lymphocytic Leukemia and the Development of Nonhematopoietic Malignancies in Eμ14-TCL1 Transgenic Mice. Cancer Research, 2006, 66, 915-920.	0.9	69
21	Disruption of miR-29 Leads to Aberrant Differentiation of Smooth Muscle Cells Selectively Associated with Distal Lung Vasculature. PLoS Genetics, 2015, 11, e1005238.	3.5	58
22	Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells. Blood, 2013, 121, 3126-3134.	1.4	57
23	MicroRNA-29b mediates altered innate immune development in acute leukemia. Journal of Clinical Investigation, 2016, 126, 4404-4416.	8.2	51
24	Hepatic miR-29ab1 expression modulates chronic hepatic injury. Journal of Cellular and Molecular Medicine, 2012, 16, 2647-2654.	3.6	50
25	Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. Breast Cancer Research and Treatment, 2011, 129, 421-432.	2.5	46
26	Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2 ^β expression levels correlate with basal phenotype in breast cancer. Cancer, 2009, 115, 899-908.	4.1	41
27	Pluripotent Stem Cell miRNAs and Metastasis in Invasive Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	37
28	Stem cell-related markers in primary breast cancers and associated metastatic lesions. Modern Pathology, 2012, 25, 949-955.	5.5	33
29	Promoter Hypomethylation and Expression Is Conserved in Mouse Chronic Lymphocytic Leukemia Induced by Decreased or Inactivated Dnmt3a. Cell Reports, 2016, 15, 1190-1201.	6.4	32
30	Hepatic Loss of miR-122 Predisposes Mice to Hepatobiliary Cyst and Hepatocellular Carcinoma upon Diethylnitrosamine Exposure. American Journal of Pathology, 2013, 183, 1719-1730.	3.8	26
31	Regulated Expression of miR-155 is Required for iNKT Cell Development. Frontiers in Immunology, 2015, 6, 140.	4.8	22
32	Common Fragile Site Tumor Suppressor Genes and Corresponding Mouse Models of Cancer. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-10.	3.0	19
33	Primary intrathyroidal paraganglioma: histopathology and novel molecular alterations. Human Pathology, 2012, 43, 2371-2375.	2.0	9
34	Gradual Rarefaction of Hematopoietic Precursors and Atrophy in a Depleted microRNA 29a, b and c Environment. PLoS ONE, 2015, 10, e0131981.	2.5	3
35	Microrna 29b Mediates Immune Evasion of Natural Killer Cells in Acute Myeloid Leukemia. Blood, 2015, 126, 207-207.	1.4	0